Bernhard J Connemann
Overview
Explore the profile of Bernhard J Connemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Zeiss R, Schonfeldt-Lecuona C, Connemann B, Hafner S, Gahr M
Front Psychiatry
. 2024 Oct;
15:1479625.
PMID: 39469476
Introduction: Antipsychotic psychopharmacotherapy is associated with the risk of drug-induced liver injury (DILI). However, understanding specific risk factors remains challenging due to limited data. This study investigates the relationship between...
3.
Zeiss R, Hafner S, Schonfeldt-Lecuona C, Connemann B, Gahr M
J Clin Psychopharmacol
. 2022 Jun;
42(5):440-444.
PMID: 35730552
Background: Drug-associated liver injury is one of the most common causes for acute liver failure and market withdrawal of approved drugs. In addition, the potential for hepatotoxicity related to specific...
4.
Elsayed M, Schonfeldt-Lecuona C, Welte X, Dardeer K, Kamal M, Abdelnaby R, et al.
Front Psychiatry
. 2022 May;
13:860683.
PMID: 35546957
Background: The COVID-19 pandemic has imposed enormous psychological discomfort and fear across the globe, including Germany. Objectives: To assess the levels of COVID-19 associated psychological distress and fear amongst Southern...
5.
Zeiss R, Connemann B, Schonfeldt-Lecuona C, Gahr M
Front Psychiatry
. 2022 Jan;
12:813879.
PMID: 34992559
[This corrects the article DOI: 10.3389/fpsyt.2021.727687.].
6.
Zeiss R, Connemann B, Schonfeldt-Lecuona C, Gahr M
Front Psychiatry
. 2021 Nov;
12:727687.
PMID: 34744821
Until now, methods of pharmacovigilance as disproportionality analysis were not capable of proving the otherwise well-established increased bleeding risk related to antidepressants (ADs). As bleeding events with ADs often occur...
7.
Gahr M, Connemann B, Muche R, Zeiss R, Wolf A
Eur J Clin Pharmacol
. 2021 Oct;
78(3):419-434.
PMID: 34705065
Purpose: In aut-idem or generic substitution, discrepancies between summaries of product characteristics (SmPCs) referring to the same active substance (AS) may cause difficulties regarding informed consent and medical liability. The...
8.
Gahr M, Connemann B, Muche R, Zeiss R
J Clin Psychopharmacol
. 2021 Jun;
41(4):470-473.
PMID: 34181363
Purpose/background: The alleged primary mechanism underlying bleeding events associated with antidepressants is inhibition of serotonin uptake in platelets resulting in reduced platelet aggregability and activity, and prolonged bleeding time. There...
9.
Zeiss R, Hiemke C, Schonfeldt-Lecuona C, Connemann B, Gahr M
Drugs Real World Outcomes
. 2021 Jun;
8(4):547-554.
PMID: 34117617
Background: To date, disproportionality analysis has been unable to demonstrate the increased bleeding risk associated with antidepressant drugs, especially selective serotonin reuptake inhibitors. Objective: We hypothesised that a potential signal...
10.
Elsayed M, Abdel-Kahaar E, Gahr M, Connemann B, Denkinger M, Schonfeldt-Lecuona C
Eur J Clin Pharmacol
. 2020 Nov;
77(5):767-775.
PMID: 33230596
Purpose: Most psychiatric drugs, such as antidepressants (AD) and antipsychotics (AP), may cause cardiac adverse events (CAE). We used summaries of product characteristics (SmPC) for assessing the likelihood of AD...